DermaLabs blends dermatologist-led science with community-powered research. Using decentralized trials, AI imaging, and SKIN token incentives, we turn everyday skincare into measurable evidence. Together, we build transparent, inclusive, and accountable pathways for discovering and validating what truly works for your skin.

GoCART Therapeutics is building a new generation of safer, smarter cell therapies for cancer. Our technology uses a biological 'AND-gate'—a two-key safety system that only activates its 'kill' signal when it detects two distinct targets on a cancer cell. This logic-gated approach dramatically reduces the toxicity risks of current CAR-T therapies.

We are developing a new gene therapy to help our canine companions stay stronger, move more comfortably, and enjoy healthier lives as they age. By supporting muscle growth, easing pain, and calming inflammation linked to arthritis, our follistatin therapy aims to improve everyday mobility and overall wellbeing.

As we age, our bodies accumulate senescent, or “zombie", cells which are highly damaged, yet refuse to die. They disrupt tissue homeostasis, are toxic to neighboring cells and are associated with numerous age-related diseases. This project will utilize CRISPR gene-editing technology to find genes that are essential for keeping senescent cells alive, thus providing new drug targets to selectively eliminate them.

Millions of people suffer from treatment-resistant PTSD with limited effective options available. Ibonova is tokenizing the development of next-generation synthetic ibogaine therapies — one of the most promising approaches for rapid and lasting trauma recovery. By creating an IP-NFT on Bio Protocol, early participants gain direct exposure to the research, data, and potential commercial upside of advancing these treatments from the lab toward real-world application.

Nootropics DAO is building the world's most effective global infrastructure for decentralized research, discovery, and commercialization of powerful solutions for human cognitive enhancement. By creating an open-science ecosystem that aligns professional researchers, citizen-scientists, and biohackers to govern a community-directed research and development pipeline with hyper-efficient feedback loops, Nootropics DAO is operating to become the dominant force in the rapidly growing nootropics industry.

Designed to accelerate agentic drug discovery pipelines in the Bio ecosystem and beyond, NeuroLab AI uses a proprietary collection of neural networks to predict the cognitive, molecular, and functional effects of any known or novel chemical compound on the human brain. Trained on a state-of-the-art biomedical knowledge graph consisting of 150,000+ nodes and over 8 million edges, NeuroLab AI produces multi-scale human and machine-readable output encompassing +400 neuroanatomical regions.

PeptAI is an autonomous AI agent that discovers new peptide drug candidates. It designs peptides computationally, then pushes them through an 8-gate validation pipeline. Every result is published on-chain (blockchain) so anyone can verify the science. Once a candidate passes validation, it's sent to the wet-lab for synthesis and binding assays. PeptAI is receptor agnostic, however first programmes target GLP1R, KISS1R, OX2R and several other GPCRs.

The first human trial that will tell you - with blood - which training actually grows your brain. 100 Berlin gym-goers. 2 training arms. 200+ BDNF blood draws. All data on-chain in real time. All revenue and dataset usage feed the Bio Protocol’s buyback & research-funding loop. 4300+ workouts already tracked. Now we ignite the next stage to reach longevity orbit.

This project will design a new RNA therapeutic that nudges the longevity-linked FOXO3 gene into its health-promoting form to halt the tissue breakdown behind degenerative disc disease—opening a precise, scalable route to drugs that extend healthspan.

Relieva is redefining therapeutic innovation through the world’s first proprietary cannabis and hemp pre-roll blend engineered for targeted pain relief. Leveraging advanced cannabinoid and terpene research, Relieva integrates scientific precision, sustainable production, and blockchain-enabled IP tokenization to establish a new benchmark in functional medicine innovation and therapeutic transparency.

The galectin-3 Inhibitors project tests a small molecule under development for peripheral indications for treating neuroinflammation in an Alzheimer’s mouse model. By blocking galectin-3, it aims to reduce brain inflammation, with potential in other neurodegenerative diseases. Galectin-3 is involved in neuroinflammation, thereby the inhibitor has a potential to be used in multiple neurodegenerative diseases.